晨鳴紙業(01812.HK):中國證監會核准公司將7.06億股境內上市外資股(B股)轉為境外上市股份(H股)
格隆匯11月22日丨晨鳴紙業(01812.HK)公吿,於2021年11月12日,公司收到中國證監會就本公司向中國證監會提交的關於B股轉換上市地方案申請的批覆函件(《關於核准山東晨鳴紙業集團股份有限公司境內上市外資股轉換上市地到香港聯合交易所主板上市的批覆》(證監許可[2021]3601號)),核准公司將現有706,385,266股境內上市外資股(B股)轉為境外上市股份(H股),併到聯交所主板上市及掛牌交易等事宜。
B股轉換上市地方案尚需(其中包括)履行聯交所及其他相關境內外監管部門要求的其他相關程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.